High co-expression of Sp1 and HER-2 is correlated with poor prognosis of gastric cancer patients

We examined the HER-2 overexpression and amplification and expression levels of Sp1 in 227 GC patients using immune-histochemical staining and fluorescence in situ hybridization. Data on clinicopathological features and relevant prognostic factors in these patients were analyzed. Of the 227 gastric cancer samples, 11.89% were positive for Her-2 overexpression/amplification under the new scoring system, and the frequency of negative, weak positive and strong positive expression of Sp1 was 14.98%, 48.01 % and 37.0% respectively.

Source: Surgical Oncology - June 3, 2015 Category: Surgery Authors: Weihua Jiang, Ziliang Jin, Fei Zhou, Jiujie Cui, Lei Wang, Liwei Wang Tags: Review Source Type: research